Alectinib: A Review in Advanced, ALK-Positive NSCLC
Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adults with advanced ALK-positive NSCLC previously treated with crizotinib. In the USA, alectinib is indicated for the treatment of adults with ALK-positive metastatic NSCLC. The recommended dosage for alectinib in the EU and USA is 600 mg twice daily. Well-designed phase III studies in patients with ALK-positive NSCLC showed that during up to ≈ 19 months’ follow-up, progression-free survival (PFS) was significantly improved with alectinib relative to crizotinib as first-line therapy (ALEX study), and relative to chemotherapy in patients previously treated with crizotinib and platinum-doublet chemotherapy (ALUR study). Central nervous system (CNS)-related outcomes were significantly improved with alectinib in both these settings. Two phase II registrational studies (NP28673 and NP28761) in patients previously treated with crizotinib also demonstrated the efficacy of alectinib, as assessed by objective response rates (ORRs), during up to 21 months’ follow-up. Overall, alectinib had a manageable tolerability profile in these settings, with most adverse events (AEs) of mild or moderate severity. Current evidence indicates that alectinib is an important treatment option for patients with advanced ALK-positive NSCLC who are previously untreated or those previously treated with crizotinib. Given its efficacy and tolerability, current guidelines include alectinib as a treatment option in these settings, with the NCCN guidelines recommending it as a preferred option for first-line therapy.
During the peer review process, the manufacturer of alectinib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Julia Paik and Sohita Dhillon are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.
- 9.National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer (version 3.2018). 2018. https://www.nccn.org/. Accessed 30 Apr 2018.
- 12.Betts K, Song J, Guo J, et al. Real-world treatment patterns and brain metastasis development in ALK-positive non-small cell lung cancer [abstract no. C10]. J Manag Care Spec Pharm. 2016;22(4):S30–1.Google Scholar
- 13.European Medicines Agency. Alecensa (alectinib): summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 2 Mar 2018.
- 14.Genentech Inc. Alecensa (alectinib): US prescribing information. 2017. https://www.accessdata.fda.gov/. Accessed 2 Mar 2018.
- 17.European Medicines Agency. Alecensa (alectinib): assessment report. 2016. http://www.ema.europa.eu/ema/. Accessed 2 Mar 2018.
- 26.Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–28.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Hsu JC, Carnac R, Henschel V, et al. Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population. J Clin Oncol. 2016;34(15 Suppl.):e20598. https://doi.org/10.1200/JCO.2017.35.15_suppl.e20616.CrossRefGoogle Scholar
- 28.Morcos PN, Dall GC, Parrott NJ, et al. Effect of food and the proton pump inhibitor (PPI) esomeprazole on the pharmacokinetics (PK) of alectinib, a highly selective ALK inhibitor, in healthy subjects [abstract no. PI-120]. Clin Pharmacol Ther. 2016;99(Suppl 1):S62–3.Google Scholar
- 33.European Medicines Agency. Alecensa (alectinib): assessment report. 2017. http://www.ema.europa.eu/ema/. Accessed 2 Mar 2018.
- 36.Barlesi F, Dingemans AMC, Yang JCH, et al. Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC) [abstract no. 1263P]. Ann Oncol. 2016;27(Suppl 6):1263P.Google Scholar
- 38.Ou S-HI, Gandhi L, Shaw A, et al. Updated pooled analysis of CNS endpoints in two phase II studies of alectinib in ALK+ NSCLC [abstract no. MA07.01]. J Thorac Oncol. 2017;12(Suppl 1):377.Google Scholar
- 44.National Institute for Health and Care Excellence. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. 2018. https://www.nice.org.uk/. Accessed 29 Jun 2018.
- 45.European Medicines Agency. Zykadia (ceritinib): summary of product characteristics. 2015. http://www.ema.europa.eu/ema/. Accessed 2 Mar 2018.
- 46.Novartis. Prescribing information for Zykadia® (ceritinib). 2017. https://www.accessdata.fda.gov/. Accessed 2 Mar 2018.